DOVATO (ViiV Healthcare Pty Ltd)
Product name
DOVATO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
201 working days (255)
Active ingredients
dolutegravir, lamivudine
Registration type
EOI
Indication
New combination
DOVATO (tablets) is indicated for the treatment of Human Immunodeficiency Virus-1 (HIV-1) infection in antiretroviral treatment-naïve adults and adolescents (from 12 years of age weighing at least 40 kg) who have no known or suspected resistance to either antiretroviral component.